The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education (YQ). Filing activity continued to slow as we near the end of 2020, with one IPO and eight SPACs...read more
Silverback Therapeutics, a Phase 1 biotech developing TLR8 agonist-antibodies for HER2/3 solid tumors, raised $242 million by offering 11.5 million shares at $21, above the range of $19 to $20. The company offered 1.5 million more shares than anticipated. It...read more
Silverback Therapeutics, a Phase 1 biotech developing TLR8 agonist-antibodies for HER2/3 solid tumors, raised the proposed deal size for its upcoming IPO on Thursday. The Seattle, WA-based company now plans to raise $195 million by offering 10 million...read more
Silverback Therapeutics, a Phase 1 biotech developing targeted immunotherapies for solid tumors, announced terms for its IPO on Monday.
The Seattle, WA-based company plans to raise $125 million by offering 7 million shares at a price range of $17 to $19. At...read more
US IPO Weekly Recap: The IPO market is taught a thing or two in an 8 IPO week
The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education (YQ). Filing activity continued to slow as we near the end of 2020, with one IPO and eight SPACs...read more
Solid tumor biotech Silverback Therapeutics prices further upsized IPO at $21, above upwardly revised range
Silverback Therapeutics, a Phase 1 biotech developing TLR8 agonist-antibodies for HER2/3 solid tumors, raised $242 million by offering 11.5 million shares at $21, above the range of $19 to $20. The company offered 1.5 million more shares than anticipated. It...read more
Solid tumor biotech Silverback Therapeutics ups proposed deal size by 56% ahead of $195 million IPO
Silverback Therapeutics, a Phase 1 biotech developing TLR8 agonist-antibodies for HER2/3 solid tumors, raised the proposed deal size for its upcoming IPO on Thursday. The Seattle, WA-based company now plans to raise $195 million by offering 10 million...read more
Solid tumor biotech Silverback Therapeutics sets terms for $125 million IPO
Silverback Therapeutics, a Phase 1 biotech developing targeted immunotherapies for solid tumors, announced terms for its IPO on Monday. The Seattle, WA-based company plans to raise $125 million by offering 7 million shares at a price range of $17 to $19. At...read more